Seeing Machines Regulatory News (SEE)

26 Oct 2009 08:25



26 October 2009

Seeing Machines Limited

("Seeing Machines" or the "Company")

TrueFIELD ANALYZER LAUNCHED

Seeing Machines Limited (AIM: SEE), a leading developer of advanced computer based imaging software systems, is pleased to announce the launch of the TrueField Analyzer (TFA), the Company's revolutionary new device for ophthalmic vision testing initially focused on the glaucoma market.  

The TFA is available initially on limited release in the United States. Following initial sales and independent clinical trials the Company intends to pursue licensing the device to a medical devices Original Equipment Manufacturer.

The TFA is the first test in the world that offers objective non-contact visual field testing which, Seeing Machines believes, has the potential to transform the diagnosis and management of a range of vision disorders.  The device offers patients the comfort and ease of a fast and simple test, and delivers clinicians an objective test that eliminates the subjective methods of traditional tests and the complications associated with these tests.  

The TFA was launched on 24 October 2009 at the American Academy of Ophthalmology (AAO) Annual Meeting in San Francisco, USA. The AAO is the largest annual gathering of ophthalmic professionals in the world and initial reaction to the TFA has been extremely positive. 

Glaucoma affects more than 2% of the world's population over the age of 40 years and vision loss due to the disease is irreversible. Early diagnosis and ongoing management, including regular vision testing and disease staging, greatly improves patient outcomes. The TFA can assist patients and clinicians in the diagnosis and management of glaucoma by significantly improving both the ease and speed of vision testing and the quality of the test results.  

Commenting on the launch Nick Cerneaz CEO of Seeing Machines said, "The launch of the TrueField Analyzer has been much anticipated and we are very pleased that it is now available for sale and grateful for the skill and efforts of our staff and partners who have contributed greatly to its development.  Beyond its initial use for glaucoma diagnosis and management the TFA will be able to assist with the diagnosis and management of other visual and neurological disorders and we are currently in the initial stages of work required to apply it to those applications."

Further information about the TFA can be obtained from the TFA website at www.truefield-analyzer.com.

Enquiries: